Material Agreements - Additional Information (Detail)				1 Months Ended						3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 06, 2022 $ / shares shares	Oct. 18, 2021 $ / shares shares	Oct. 29, 2020 USD ($)	Aug. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	May 31, 2021 USD ($)	Mar. 31, 2021 USD ($) tranche shares	Aug. 31, 2020 USD ($) shares	Oct. 31, 2019 USD ($) tranche shares	Jun. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Feb. 28, 2023 USD ($)	Oct. 12, 2021 shares	Nov. 30, 2020 USD ($)
License And Other Related Agreements [Line Items]
Number of tranches | tranche							3		3
QED
License And Other Related Agreements [Line Items]
Payment towards development amount in connection with license agreement										$ 0	$ 0
QED | Subsequent Event
License And Other Related Agreements [Line Items]
Payment towards research and development amount in connection with license agreement				$ 1,500,000
Myokardia
License And Other Related Agreements [Line Items]
Payment towards development amount in connection with license agreement										0	0
Navire
License And Other Related Agreements [Line Items]
Payment towards development amount in connection with license agreement										0	0
Tarsus Pharmaceuticals
License And Other Related Agreements [Line Items]
Payment towards development amount in connection with license agreement											2,500,000
Landos
License And Other Related Agreements [Line Items]
Payment towards development amount in connection with license agreement										0	0
NImmune
License And Other Related Agreements [Line Items]
Payment towards development amount in connection with license agreement										0	0
Nanobiotix
License And Other Related Agreements [Line Items]
Payment towards development amount in connection with license agreement										0	0
Lyra
License And Other Related Agreements [Line Items]
Payment towards development amount in connection with license agreement										0	0
Tarsus Warrants
License And Other Related Agreements [Line Items]
Number of securities called by each warrant or right (in shares) | shares		156,746
Navire | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement								$ 8,000,000
Payment towards development amount in connection with license agreement													$ 8,500,000
Navire | Maximum | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales								15.00%
Navire | Minimum | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales								5.00%
Navire | Specified Development Regulatory Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount								$ 24,500,000
Navire | Sales Based Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone								357,600,000
QED | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement									$ 10,000,000
QED | Specified Development Regulatory Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount									7,000,000
QED | Sales Based Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone									87,500,000
QED | Lian Oncology | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants and rights outstanding value									$ 1,000,000
Class of warrants or rights expiry period									10 years
QED | Lian Oncology | Tranche One | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity									10.00%
QED | Lian Oncology | Tranche Two | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity									10.00%
QED | Lian Oncology | Tranche Three | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity									10.00%
QED | Lian Oncology | Warrants To Purchase Common Stock | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares		347,569							100,000
Class of warrants or rights exercise price (in dollars per share) | $ / shares		$ 0.000017100448
Myokardia
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement								40,000,000
Myokardia | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount								60,000,000
Payment of milestone amount												$ 5,000,000.0
Myokardia | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone								87,500,000
Myokardia | Non Refundable Financing Milestone Payment
License And Other Related Agreements [Line Items]
Milestone payment payable								35,000,000
Imputed interest on milestone payment								$ 2,300,000
Myokardia | Non Refundable Financing Milestone Payment | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Payment of milestone amount			$ 35,000,000
Myokardia | Warrants To Purchase Common Stock
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares								170,000							170,000
Warrants and rights outstanding value								$ 33,800,000
Warrants or rights issuable as a percentage of fully diluted equity								17.00%
Pfizer
License And Other Related Agreements [Line Items]
Commitment to contribute capital																$ 70,000,000
Upfront payment receivable					$ 20,000,000							20,000,000				$ 20,000,000
Milestone continent consideration					$ 135,000,000
Tarsus Pharmaceuticals
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement							$ 15,000,000
Payment of milestone amount										0	0	$ 25,000,000
Tarsus Pharmaceuticals | Milestone Stage Two
License And Other Related Agreements [Line Items]
Milestone payment payable							10,000,000
Tarsus Pharmaceuticals | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount							75,000,000
Tarsus Pharmaceuticals | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone							100,000,000
Tarsus Pharmaceuticals | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount							$ 175,000,000
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares							125,000
Warrants and rights outstanding value							$ 9,400,000
Class of warrants or rights expiry period							10 years
Class of warrants or rights exercise price (in dollars per share) | $ / shares	$ 0.000017100448	$ 0.000017100448
Warrants issued during period (in shares) | shares	1	2					3
Issuance of ordinary shares upon initial public offering, net of issuance costs (in shares) | shares	78,373	78,373
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche One
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity							12.50%
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche Two
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity							12.50%
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche Three
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity							12.50%
Landos
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement						$ 18,000,000
Landos | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						95,000,000
Landos | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone						105,000,000
Landos | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						200,000,000
N1mmune
License And Other Related Agreements [Line Items]
Payment towards development amount in connection with license agreement										$ 0	$ 0
N1mmune | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount														$ 45,000,000
N1mmune | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone														105,000,000
N1mmune | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount														$ 150,000,000
Nanobiotix
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement						$ 20,000,000
Nanobiotix | Maximum
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales						13.00%
Nanobiotix | Minimum
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales						10.00%
Nanobiotix | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						$ 65,000,000
Nanobiotix | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone						155,000,000
Nanobiotix | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						220,000,000
Lyra
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement						12,000,000
Lyra | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						40,000,000
Lyra | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone						95,000,000
Lyra | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						$ 135,000,000